IMRN News and Press, Immuron Limited From 04/11/23

MELBOURNE, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is ple...

Highlights: Australian Q3 FY23 sales of A$577 k (201% of 1H sales) North American Q3 FY23 Travelan ® sales of A$298 k (100% of 1H sales) Global Q3 YTD FY23 sales of A$1.46 M represent an increase of 239% compared with the corresponding period in FY22 of A$43...

MELBOURNE, Australia, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, invites ...

Immuron ( NASDAQ: IMRN ) said it submitted a response to the U.S. Food and Drug Administration (FDA) related to the clinical hold placed by the agency on the start of trials of an oral antibacterial drug. The FDA had notified the company and the US Naval Medical Research Center (NMRC)...

MELBOURNE, Australia, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, today a...

Highlights: First participants enrolled in USU Travelan Clinical Trial Field Study 157 participants successfully randomized into the Clinical Study Plans in place to enrol in 1302 healthy volunteers in total Infectious diarrhea is the most common illness repo...

Immuron ( NASDAQ: IMRN ) said it received a European Patent for compositions and methods for treating and/or preventing Clostridioides difficile associated disease. The Patent 14784945.9 titled 'Methods and Compositions for the treatment and/or prophylaxis of Clostridiu...

MELBOURNE, Australia, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is plea...

3 Top Indicators That Penny Stocks Traders Need to Understand Penny stock traders must be vigilant in monitoring the market to spot good opportunities. To help them make informed decisions, they use a variety of indicators. The following are some of the top indicators that penny stock traders...

Australian biotech Immuron Limited ( NASDAQ: IMRN ) gained ~47% pre-market Friday after announcing that the FDA greenlighted its Investigational New Drug (IND) application to study OTC medicine Travelan as a treatment to prevent infectious diarrhea. Accordingly, Immuron ( IMRN ...